Literature DB >> 24060536

A real-time killing assay to follow viral epitope presentation to CD8 T cells.

Pauline Gourdain1, Julie Boucau, Georgio Kourjian, Nicole Y Lai, Ellen Duong, Sylvie Le Gall.   

Abstract

The ability of cytotoxic T lymphocytes (CTL) to clear virus-infected cells requires the presentation of viral peptides intracellularly processed and displayed by major histocompatibility complex class I. Assays to measure CTL-mediated killing often use peptides exogenously added onto target cells--which does not account for epitope processing--or follow killing of infected cells at a single time point. In this study we established a real-time fluorogenic cytotoxic assay that measures the release of the Glucose-6-phosphate-dehydrogenase by dying target cells every 5 min after addition of CTL. It has comparable sensitivity to (51)chromium-based killing assay with the additional advantage of incorporating the kinetics of epitope presentation. We showed that HIV infection of immortalized or primary CD4 T cells leads to asynchronous killing by two CTL clones specific for epitopes located in different proteins. Real-time monitoring of killing of virus-infected cells will enable identification of immune responses efficiently preventing virus dissemination.
© 2013.

Entities:  

Keywords:  7-AAD; 7-amino-actinomycin D; Antigen processing; CAM; CD8 T cells; CFSE; Cytotoxicity; G6PDH; HIV; Kinetics; MTG; MitoTrackerGreen; Real-time killing assay; calceinacetoxymethylester; carboxyfluorescein succinimidyl ester; glucose 6-phosphate dehydrogenase

Mesh:

Substances:

Year:  2013        PMID: 24060536      PMCID: PMC3845008          DOI: 10.1016/j.jim.2013.09.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  43 in total

1.  Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.

Authors:  Luzheng Liu; Ann Chahroudi; Guido Silvestri; Mary E Wernett; William J Kaiser; Jeffrey T Safrit; Akira Komoriya; John D Altman; Beverly Z Packard; Mark B Feinberg
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

2.  An improved resazurin-based cytotoxicity assay for hepatic cells.

Authors:  M K McMillian; L Li; J B Parker; L Patel; Z Zhong; J W Gunnett; W J Powers; M D Johnson
Journal:  Cell Biol Toxicol       Date:  2002       Impact factor: 6.691

3.  High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control.

Authors:  Zaza M Ndhlovu; Lori B Chibnik; Jacqueline Proudfoot; Seanna Vine; Ashley McMullen; Kevin Cesa; Filippos Porichis; R Brad Jones; Donna Marie Alvino; Meghan G Hart; Eleni Stampouloglou; Alicja Piechocka-Trocha; Carl Kadie; Florencia Pereyra; David Heckerman; Philip L De Jager; Bruce D Walker; Daniel E Kaufmann
Journal:  Blood       Date:  2012-12-11       Impact factor: 22.113

4.  How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?

Authors:  S L Rowland-Jones; S Pinheiro; R Kaul; P Hansasuta; G Gillespie; T Dong; F A Plummer; J B Bwayo; S Fidler; J Weber; A McMichael; V Appay
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

5.  Frequency and function of HIV-specific CD8(+) T cells.

Authors:  S A Migueles; M Connors
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

6.  High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells.

Authors:  Z Zhang; K Apse; J Pang; R C Stanton
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

7.  A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity.

Authors:  H Lecoeur; M Février; S Garcia; Y Rivière; M L Gougeon
Journal:  J Immunol Methods       Date:  2001-07-01       Impact factor: 2.303

8.  Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide.

Authors:  A E Lee-MacAry; E L Ross; D Davies; R Laylor; J Honeychurch; M J Glennie; D Snary; R W Wilkinson
Journal:  J Immunol Methods       Date:  2001-06-01       Impact factor: 2.303

9.  Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.

Authors:  Xu G Yu; Marylyn M Addo; Eric S Rosenberg; William R Rodriguez; Paul K Lee; Cecily A Fitzpatrick; Mary N Johnston; Daryld Strick; Philip J R Goulder; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.

Authors:  Matilu Mwau; Andrew J McMichael; Tomás Hanke
Journal:  AIDS Res Hum Retroviruses       Date:  2002-06-10       Impact factor: 2.205

View more
  3 in total

1.  Sequence-specific alterations of epitope production by HIV protease inhibitors.

Authors:  Georgio Kourjian; Yang Xu; Ijah Mondesire-Crump; Mariko Shimada; Pauline Gourdain; Sylvie Le Gall
Journal:  J Immunol       Date:  2014-03-10       Impact factor: 5.422

2.  HIV Protease Inhibitor-Induced Cathepsin Modulation Alters Antigen Processing and Cross-Presentation.

Authors:  Georgio Kourjian; Marijana Rucevic; Matthew J Berberich; Jens Dinter; Daniel Wambua; Julie Boucau; Sylvie Le Gall
Journal:  J Immunol       Date:  2016-03-23       Impact factor: 5.422

3.  A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity.

Authors:  Nadine Nelson; Marta Lopez-Pelaez; Asis Palazon; Edmund Poon; Maike De La Roche; Simon Barry; Viia Valge-Archer; Robert W Wilkinson; Simon J Dovedi; Paul D Smith
Journal:  Oncoimmunology       Date:  2019-04-26       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.